Maplight Therapeutics (MPLT)CFO sold ~$28K

~$28K

Approx. value · 968 sh @ $29.00

367K

Holds after · shares reported

Traded

May 5, 2026

Filed

May 7, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 26, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
2. Apr 15, 2026Insider · 8 peopleInsiders: 8 sales (~$879K)
3. Apr 16, 2026Insider · 5 peopleInsiders: 10 sales (~$395K)
4. Apr 23, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the “Board”) of MapLight Therapeutics, Inc. (the “Company”) of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.”
5. Apr 27, 2026Insider · 2 peopleInsiders: 6 sales (~$2.9M)
6. Apr 28, 2026Insider · 1 personInsiders: 2 sales (~$544K)
7. May 4, 2026Insider · 5 peopleInsiders: 20 sales (~$2.1M)
8. May 5, 2026 · this disclosureInsiderCFO sold ~$28K of MPLT shares in the open market

What came next

1. May 5, 2026Insider · 4 peopleInsiders: 7 sales (~$1.2M)
2. May 6, 2026Insider · 4 peopleInsiders: 8 sales (~$2.4M)
3. May 7, 2026Insider · 3 peopleInsiders: 5 sales (~$723K)
4. May 8, 2026Insider · 1 personInsiders: 3 sales (~$953K)
5. May 11, 2026Insider · 2 peopleInsiders: 8 sales (~$840K)
6. May 14, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
7. May 18, 2026Insider · 1 personInsiders: 2 sales (~$3.2M)
8. Jun 18, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 18, 2026, Vishwas Setia was separated as the Chief Financial Officer of MapLight Therapeutics, Inc. (the “Company”), effective immediately, following a review of a human resources violation.”
9. Aug 13, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 2 more items)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Maplight Therapeutics

For Maplight Therapeutics, OQRO holds 52 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MPLT page.

Other recent filings by Vishwas Setia, Chief Financial Officer

• SEC Form 4 at Maplight Therapeutics (MPLT)May 7, 2026
• SEC Form 4 at Maplight Therapeutics (MPLT)May 7, 2026
• SEC Form 4 at Maplight Therapeutics (MPLT)May 7, 2026
• SEC Form 4 at Maplight Therapeutics (MPLT)May 7, 2026
• SEC Form 4 at Maplight Therapeutics (MPLT)May 7, 2026

The full history of Vishwas Setia, Chief Financial Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Maplight Therapeutics

• SEC Form 4Sep 18, 2026
• SEC Form 4Aug 18, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 4Aug 5, 2026
• SEC Form 4Jul 30, 2026
• SEC Form 4Jul 30, 2026

Everything OQRO holds on this company is on its MPLT page.